Osteonecrosis of the jaw: Effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism

Journal of Oral and Maxillofacial Surgery

Volumn 68, Issue 11, 2010, Pages 2837-2845

  Otto, Sven ^a   Pautke, Christoph ^a   Opelz, Christine ^b   Westphal, Ines ^b   Drosse, Inga ^c   Schwager, Joanna ^b   Bauss, Frieder ^b   Ehrenfeld, Michael ^c   Schieker, Matthias ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLODRONIC ACID; IBANDRONIC ACID; ZOLEDRONIC ACID;

ARTICLE; BONE REGENERATION; CELL ACTIVITY; CELL IMMORTALIZATION; CELL MOTILITY; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; HUMAN; HUMAN CELL; IN VITRO STUDY; JAW OSTEONECROSIS; MESENCHYMAL STEM CELL; MICROSCOPY; MULTIPOTENT STEM CELL; OSTEOCLAST; PATHOPHYSIOLOGY; PH; WOUND HEALING;

BONE DENSITY CONSERVATION AGENTS; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; CELL SHAPE; CELL SURVIVAL; CLODRONIC ACID; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUORESCENT DYES; HUMANS; HYDROGEN-ION CONCENTRATION; IMIDAZOLES; JAW DISEASES; MESENCHYMAL STEM CELLS; OSTEONECROSIS; TIME FACTORS;

EID: 77958530598     PISSN: 02782391     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joms.2010.07.017     Document Type: Article

References (53)

1. R.E. Marx Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic J Oral Maxillofac Surg 61 2003 1115
2. J. Wang, N.M. Goodger, and M.A. Pogrel Osteonecrosis of the jaws associated with cancer chemotherapy J Oral Maxillofac Surg 61 2003 1104
3. C.A. Migliorati Bisphosphanates and oral cavity avascular bone necrosis J Clin Oncol 21 2003 4253
4. S. Khosla, D. Burr, and J. Cauley Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research J Bone Miner Res 22 2007 1479
5. S.L. Ruggiero, T.B. Dodson, and L.A. Assael American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws2009 update J Oral Maxillofac Surg 67 2009 2
6. S. Otto, S. Hafner, and K.A. Grotz The role of inferior alveolar nerve involvement in bisphosphonate-related osteonecrosis of the jaw J Oral Maxillofac Surg 67 2009 589
7. M.H. Abu-Id, P.H. Warnke, and J. Gottschalk "Bis-phossy jaws"High and low risk factors for bisphosphonate-induced osteonecrosis of the jaw J Craniomaxillofac Surg 36 2008 95
8. A. Bamias, E. Kastritis, and C. Bamia Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors J Clin Oncol 23 2005 8580
9. T. Boonyapakorn, I. Schirmer, and P.A. Reichart Bisphosphonate-induced osteonecrosis of the jaws: Prospective study of 80 patients with multiple myeloma and other malignancies Oral Oncol 44 2008 857
10. C. Walter, B. Al-Nawas, and K.A. Grotz Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate Eur Urol 54 2008 1066
11. E.P. Wang, L.B. Kaban, and G.J. Strewler Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy J Oral Maxillofac Surg 65 2007 1328
12. A. Badros, E. Terpos, and E. Katodritou Natural history of osteonecrosis of the jaw in patients with multiple myeloma J Clin Oncol 26 2008 5904
13. A. Kyrgidis, K. Vahtsevanos, and G. Koloutsos Bisphosphonate-related osteonecrosis of the jaws: A case-control study of risk factors in breast cancer patients J Clin Oncol 26 2008 4634
14. J.C. Lo, F.S. O'Ryan, and N.P. Gordon Predicting risk of osteonecrosis of the jaw with oral Bisphosphonate Exposure (PROBE) Investigators Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure J Oral Maxillofac Surg 68 2010 243
15. M.M. McDonald, S. Dulai, and C. Godfrey Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling Bone 43 2008 653
16. R.S. Weinstein, P.K. Roberson, and S.C. Manolagas Giant osteoclast formation and long-term oral bisphosphonate therapy N Engl J Med 360 2009 53
17. I.R. Reid, M.J. Bolland, and A.B. Grey Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 41 2007 318
18. R. Landesberg, M. Cozin, and S. Cremers Inhibition of oral mucosal cell wound healing by bisphosphonates J Oral Maxillofac Surg 66 2008 839
19. B.O. Cetinkaya, G.C. Keles, and B. Ayas Effects of risedronate on alveolar bone loss and angiogenesis: A stereologic study in rats J Periodontol 79 2008 1950
20. M.M. Deckers, E.R. Van Beek, and G. Van Der Pluijm Dissociation of angiogenesis and osteoclastogenesis during endochondral bone formation in neonatal mice J Bone Miner Res 17 2002 998
21. T. Hansen, M. Kunkel, and A. Weber Osteonecrosis of the jaws in patients treated with bisphosphonatesHistomorphologic analysis in comparison with infected osteoradionecrosis J Oral Pathol Med 35 2006 155
22. A.M. Wolf, H. Rumpold, and H. Tilg The effect of zoledronic acid on the function and differentiation of myeloid cells Haematologica 91 2006 1165
23. A.J. Roelofs, M. Jauhiainen, and H. Monkkonen Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP Br J Haematol 144 2009 245
24. S. Otto, S. Hafner, and G. Mast Bisphosphonate-related osteonecrosis of the jaw: Is pH the missing part in the pathogenesis puzzle? J Oral Maxillofac Surg 68 2010 1158
25. R.G. Russell, N.B. Watts, and F.H. Ebetino Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy Osteoporos Int 19 2008 733
26. R. Rizzoli, N. Burlet, and D. Cahall Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis Bone 42 2008 841
27. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws J Oral Maxillofac Surg 65 2007 369
28. W. Bocker, D. Docheva, and W.C. Prall IKK-2 is required for TNF-alpha-induced invasion and proliferation of human mesenchymal stem cells J Mol Med 86 2008 1183
29. F. Bauss, T. Pfister, and S. Papapoulos Ibandronate uptake in the jaw is similar to long bones and vertebrae in the rat J Bone Miner Metab 26 2008 406
30. G.H. Nancollas, R. Tang, and R.J. Phipps Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite Bone 38 2006 617
31. C.T. Leu, E. Luegmayr, and L.P. Freedman Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy Bone 38 2006 628
32. F. Bauss, and R.G. Russell Ibandronate in osteoporosis: Preclinical data and rationale for intermittent dosing Osteoporos Int 15 2004 423
33. E. Volkmer, I. Drosse, and S. Otto Hypoxia in static and dynamic 3D culture systems for tissue engineering of bone Tissues Eng A 14 2008 1331
34. C. Walter, M.O. Klein, and A. Pabst Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells Clin Oral Investig 14 2010 35
35. A. Luhe, K.P. Kunkele, and M. Haiker Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: Implications for renal safety Toxicol Vitro 22 2008 899
36. P. Sansoni, G. Passeri, and F. Fagnoni Inhibition of antigen-presenting cell function by alendronate in vitro J Bone Miner Res 10 1995 1719
37. J. Yamada, N.H. Tsuno, and J. Kitayama Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation J Surg Res 151 2009 115
38. G. Duque, and D. Rivas Alendronate has an anabolic effect on bone through the differentiation of mesenchymal stem cells J Bone Miner Res 22 2007 1603
39. X. Shi, Y. Wang, and R.R. Varshney In-vitro osteogenesis of synovium stem cells induced by controlled release of bisphosphate additives from microspherical mesoporous silica composite Biomaterials 30 2009 3996
40. A. Badros, D. Weikel, and A. Salama Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors J Clin Oncol 24 2006 945
41. A. Vignery, and R. Baron Dynamic histomorphometry of alveolar bone remodeling in the adult rat Anat Rec 196 1980 191
42. L.P. Garetto, and N.D. Tricker Remodeling of bone surrounding the implant interface L.P. Garetto, C.H. Turner, R.L. Duncan, Bridging Gap Between Dental and Orthopaedic Implants Proceedings of the 3rd Annual Indiana Conference, May 12-16, 1998 1998 Indiana University School of Dentistry Indianapolis, IN
43. S.S. Huja, S.A. Fernandez, and K.J. Hill Remodeling dynamics in the alveolar process in skeletally mature dogs Anat Rec A Discov Mol Cell Evol Biol 288 2006 1243
44. T. Hoffmann, M. John, and T. Kerschbaum Oral epidemiology W. Micheelis, U. Schiffner, Institite of German Dentists: Fourth German Oral Health Study (DMS IV) 2006 Deutscher Zahnrzte Verlag DV Cologne
45. 2, pH, and redox potential of experimental abscesses Proc Soc Exp Biol Med 147 1974 29
46. P. Bertram, K.H. Treutner, and B. Klosterhalfen [Artificial pressure increase in subcutaneous abscess with evidence of general systemic reaction] Langenbecks Arch Chir 382 1997 291
47. K.G. Wiese [Electrolyte concentration, real and osmotic pressure in abscesses] Zentralbl Chir 119 1994 54
48. A.O. Hoff, B.B. Toth, and K. Altundag Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates J Bone Miner Res 23 2008 826
49. L.M. Hess, J.M. Jeter, and M. Benham-Hutchins Factors associated with osteonecrosis of the jaw among bisphosphonate users Am J Med 121 2008 475
50. M.A. Dimopoulos, E. Kastritis, and C. Bamia Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid Ann Oncol 20 2009 117
51. M. Sato, W. Grasser, and N. Endo Bisphosphonate action: Alendronate localization in rat bone and effects on osteoclast ultrastructure J Clin Invest 88 1991 2095
52. P. Lesclous, S.A. Najm, and J.P. Carrel Bisphosphonate-associated osteonecrosis of the jaw: A key role of inflammation? Bone 45 2009 843
53. M.J. Rogers, S. Gordon, and H.L. Benford Cellular and molecular mechanisms of action of bisphosphonates Cancer 88 2000 2961